Антифосфолипидный синдром: диагностика, механизм развития, вопросы терапии

УДК 616-005.6:616.151.5:612.115.3

Аннотация

Резюме. Приведен обзор литературы по механизму развития антифосфолипидного синдрома (АФС), тактика терапии. Представлены последние рекомендации Европейской антиревматической лиги (англ. European League Against Rheumatism, EULAR) по профилактике и лечению тромбозов при АФС. Обсуждены вопросы целесообразности терапии иммуносупрес- сивными препаратами при АФС.

Литература

1. Решетняк Т.М. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56–71. DOI: 10.14412/1995–4484–2014–56–71.
2. Miyakis S., Lockshin M.D. Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295– 306. DOI:10.1111/j.1538–7836.2006.01753.
3. Cervera R., Espinosa G., Reverter J.C. Antiphospholipid syndrome in systemic autoimmune diseases. In: Handbook of systemic autoimmune diseases. Eds. R. Cervera, J.C. Reverter, M.A. Khamashta. Amsterdam: Elsevier, 2009. Vol. 12:105–16. DOI: 10.1016/S1571–5078(08)00408-X.
4. Asherson R.A. New subsets of the antiphospholipid syndrome in 2006: “PRE-APS” (probable APS) and microangiopathic antiphospholipid syndromes (“MAPS”). Autoimmun Rev. 2006;6(2):76–80. DOI: 10.1016/j.autrev.2006.06.008.
5. Cervera R., Serrano R., Pons-Estel G.J. et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011–8. DOI: 10.1136/annrheumdis-2013–204838.
6. Pengo V., Ruffatti A., Legnani C. et al. Clinical course of high risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237–42. DOI: 10.1111/j.1538–7836.2009.03674.x.
7. Biggioggero M., Meroni P.L. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev. 2010;9(5): A299– 304. DOI: 10.1016/j.autrev.2009.11.013.
8. Mehrani T., Petri M. Epidemiology of the antiphospholipid syndrome. In: Handbook of systemic autoimmune diseases. Eds. R. Cervera, J.C. Reverter, M.A. Khamashta. Elsevier, 2009. Vol. 10:13–34. DOI: 10.1016/S1571–5078(08)00402–9.
9. Pengo V., Ruffatti A., Legnani C. et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714–8. DOI: 10.1182/blood-2011–03–340232.
10. Cohen H., Efthymiou M., Isenberg D.A. Use of direct oral anticoagulants in antiphospholipid syndrome. J Thromb Haemost. 2018;16(6):1028–39. DOI: 10.1111/jth.14017.
11. Kearon C., Parpia S., Spencer F.A. et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 2018;131(19):2151–60. DOI: 10.1182/blood-2017–09–805689.
12. Taraborelli M., Reggia R., Dall’Ara F. et al. Longterm outcome of patients with primary antiphospholipid syndrome: a retrospective multicenter study. J Rheumatol. 2017;44(8):1165–72. DOI: 10.3899/jrheum.161364.
13. Tincani A., Andreoli L., Casu C. et al. Antiphospholipid antibody profile: implications for the evaluation and management of patients. Lupus. 2010;19(4):432–5. DOI: 10.1177/0961203310361491.
14. White C.W., Thomason A.R., Boyd K. Role of novel oral anticoagulants in the treatment of antiphospholipid syndrome. Hosp Pharm. 2016;51(9):759–67. DOI: 10.1310/hpj5109–759.
15. Legault K., Schuneman H., Hills C. et al. McMaster RARE-Best practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost. 2018 Jun 7. DOI: 10.1111/jth.14192. [Epub ahead of print].
16. Espinosa G., Rodríguez-Pintó I., Cervera R. Catastrophic antiphospholipid syndrome: an update. Panminerva Med. 2017;59(3):254–68.
17. Espinosa G., Bucciarelli S., Cervera R. et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63(6):730–6. DOI: 10.1136/ard.2003.007245.
18. Asherson R. A., Pierangel S. S., Cervera R. Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis. 2007;66(4):429–33. DOI: 10.1136/ard.2006.067033.
19. Asherson R.A., Cervera R. Microvascular and microangiopathic antiphospholipid-associated syndromes (“MAPS”): semantic or antisemantic? Autoimmun Rev. 2008;7(3):164–7. DOI: 10.1016/j.autrev.2007.11.009.
20. Artim-Esen B., Diz-Küçükkaya R., İnanç M. The significance and management of thrombocytopenia in antiphospholipid syndrome. Curr Rheumatol Rep. 2015;17(3):14. DOI: 10.1007/s11926– 014–0494–8.
21. Lechner K., Pabinger-Fasching I. Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature. Haemostasis. 1985;15(4):254–62. DOI: 10.1159/000215157.
22. Finazzi G. The Italian Registry of Antiphospholipid Antibodies. Haematologica. 1997;82(1):101–5.
23. Diz-Küçükkaya R., Hacihanefioğlu A., Yenerel M. et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98(6):1760–4. DOI: 10.1182/blood. v98.6.1760.
24. Scaramucci L., Giovannini M., Niscola P. et al. IgA-induced autoimmune hemolytic anemia in a patient with antiphospholipid syndrome. Asian J Transfus Sci. 2012;6(2):188. DOI: 10.4103/0973– 6247.98950.
25. Hughes syndrome: antiphospholipid syndrome. Ed. M.A. Khamashta. London: Springer, 2000. 474 s.
26. Насонов Е.Л. Антифосфолипидный синдром. М.: Литтера, 2004. 440 c.
27. Chighizola C. B., Raschi E., Borghi M. O., Meroni P. L. Update on the pathogenesis and treatment of the antiphospholipid syndrome. Curr Opin Rheumatol. 2015;27(5):476–82. DOI: 10.1097/BOR.0000000000000200.
28. Van den Hoogen L.L., van Laar J.M. Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjeogren’s syndrome. Best Pract Res Clin Rheumatol. 2020;34(1):101485. DOI: 10.1016/j.berh.2020.101485.
29. Решетняк Т.М., Штивельбанд И.Б., Середавкина Н.В. и др. Диагностические критерии антифосфолипидного синдрома: сравнительная оценка критериев 1999 и 2006 гг. (ретроспективное исследование). Тромбоз, гемостаз и реология. 2016;(3):20–9. DOI: 10.25555/THR.2017.3.0790.
30. Erkan D., Salmon J., Lockshin M. Antiphospholipid syndrome. In: Kelley and Firestein’s textbook of rheumatology. Eds. G.S. Firestein, I.B. McInnes, J.R. O’Dell. Philadelphia: Elsevier, 2017. 1389–99.
31. da Silva F.F., Levy R.A., de Carvalho J.F. Cardiovascular risk factors in the antiphospholipid syndrome. J Immunol Res. 2014;2014:621270. DOI: 10.1155/2014/621270.
32. Bouma B., de Groot P.G., van den Elsen J.M. et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipid based on its crystal structure. EMBO J. 1999;18(19):5166–74. DOI: 10.1093/emboj/18.19.5166.
33. Brighton T.A., Hogg P.J., Dai Y.P. et al. Beta 2-glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant. Br J Haematol. 1996;93:185–94. DOI: 10.1046/j.1365–2141.1996.446981.x.
34. Benhamou Y., Bellien J., Armengol G. et al. Role of Toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome. Arthritis Rheumatol. 2014;66(11):3210–20. DOI: 10.1002/art.38785.
35. Artenjak A., Locatelli I., Brelih H. et al. Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I. Immunol Res. 2015;61(1–2):35–44. DOI: 10.1007/s12026–014–8578–0.
36. Arvieux J., Renaudineau Y., Mane I. et al. Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Haemost. 2002;87(4):599–605.
37. Girardi G., Berman J., Redecha P. et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003;112(11):1644–54. DOI: 10.1172/JCI18817.
38. Fischetti F., Durigutto P., Pellis V. et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005;106(7):2340–6. DOI: 10.1182/blood-2005–03–1319.
39. Чельдиева Ф.А., Решетняк Т.М. Ревматоидный артрит: некоторые компоненты гемостаза и воспаление. Современная ревматология. 2019;13(3):87–94. DOI: 10.14412/1996–7012–2019– 3–87–94.
40. Xia L., Zhou H., Wang T. et al. Activation of mTOR is involved in anti-β2GPI/β2GPI-induced expression of tissue factor and IL-8 in monocytes. Thromb Res. 2017;157:103–10. DOI: 10.1016/j. thromres.2017.05.023.
41. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1(6): a001651. DOI: 10.1101/cshperspect.a001651.
42. Решетняк Т.М., Острякова Е.В., Патрушева Н.Л. и др. Полиморфизм гена ингибитора активатора плазминогена типа 1 и тромбозы у больных антифосфолипидным синдромом. Терапевтический архив. 2013;85(1):76–84.
43. Насонов Е.Л., Решетняк Т.М., Патрушев Л.И. и др. Мутации Leiden, G20210А в гене протромбина и антифосфолипидные антитела при системной красной волчанке и антифосфолипидном синдроме. Терапевтический архив. 2000;(5):34–8. Nasonov E.L., Reshetnyak T.M., Patrushev L.I. et al. Leiden mutations, G20210A in the prothrombin gene and antiphospholipid antibodies in systemic lupus erythematosus and antiphospholipid syndrome. Terapevticheskij arhiv. 2000;(5):34–8. (In Russ.).
44. Reshetnyak T. M., Seredavkina N. V., Satybaldyeva M. A. et al. Liver transplantation in a patient with primary antiphospholipid syndrome and Budd-Chiari syndrome. World J Hepatol. 2015;7(19):2229–36. DOI: 10.4254/wjh.v7.i19.2229.
45. Tektonidou M.G., Andreoli L., Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296–304. DOI: 10.1136/annrheumdis-2019–215213.
46. Кондратьева Л.В., Решетняк Т.М. Профилактика тромбозов при антифосфолипидном синдроме. Современная ревматология. 2009;3(3):18–22. DOI: 10.14412/1996–7012–2009–552. Kondratyeva L.V., Reshetnyak T.M. Prevention of thrombosis in antiphospholipid syndrome. Sovremennaya revmatologiya. 2009;3(3):18–22. (In Russ.). DOI: 10.14412/1996–7012–2009–552.
47. Jackson W.G., Oromendia C., Unlu O. et al. Antiphospholipid syndrome alliance for clinical trials and international networking. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv. 2017;1(25):2320–4. DOI: 10.1182/bloodadvances.2017008185.
48. Garcia D., Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010–21. DOI: 10.1056/NEJMra1705454.
49. Almutairi A.R., Zhou L., Gellad W.F. et al. Effectiveness and safety of non–vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. Clin Ther. 2017;39(7):1456–78.e36. DOI: 10.1016/j. clinthera.2017.05.358.
50. Сатыбалдыева М.А., Решетняк Т.М. Новые оральные антикоагулянты в терапии антифосфосфолипидного синдрома. Научно-практическая ревматология. 2016;54(2):219–26. DOI: 10.14412/1995–4484–2016–219–226.
51. Almarshad F., Alaklabi A., Bakhsh E. et al. Use of direct oral anticoagulants in daily practice. Am J Blood Res. 2018;8(4):57–72. 52. Ros O., Marce S.J.C., Hernande C.J. New oral anticoagulants in antiphospholipid syndrome treatment. Int J Intern Emerg Med. 2019;2(1):1017.
52. PRAC recommendations on signals. European Medicines Agency, 2019. 8 pp. Available at: https://www.ema.europa.eu/en/documents / prac-recommendation / prac-recommendations-signals-adopted-8–11-april-2019-prac-meeting_en.pdf. [Accessed: 10.04.2020].
53. Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome. Medicines and Healthcare Products Regulatory Agency, 2019. Available at: https://www.gov.uk/drug-safety-update/direct-acting-oral-anticoagulants-doacs-increased-risk-of-recurrent-thrombotic-events-in-patients-with-antiphospholipid-syndrome. [Accessed: 10.04.2020].
54. Arachchillage D.J., Gomez K., Alikhan R. et al. Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br J Haematol. 2012;157:47–58): use of direct acting oral anticoagulants. Br J Haematol. 2020;189(2):212–5. DOI: 10.1111/bjh.16308.
55. Favaloro E.J., Mohammed S., Curnow J., Pasalic L. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives. Pathology. 2019;51(3):292–300. DOI: 10.1016/j. pathol.2018.11.008.
56. Cervera R., Roddriguez-Pinto L., Colafrancesco S. et al. 14th International Congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Autoimmun Rev. 2014;13(7):699–707. DOI: 10.1016/j.autrev.2014.03.002.
57. Van den Hoogen L.L., van Roon J.A.G., Radstake T.R.D.J. et al. Delineating the deranged immune system in the antiphospholipid syndrome. Autoimmun Rev. 2016;15(1):50–60. DOI: 10.1016/j.autrev.2015.08.011.
58. Dobrowolski C., Erkan D. Treatment of antiphospholipid syndrome beyond anticoagulation. Clin Immunol. 2018;206:56–62. DOI: 10.1016/j.clim.2018.03.001.
59. Schmidt-Tanguy A., Voswinkel J., Henrion D. et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost. 2013;11(10):1927–9. DOI: 10.1111/jth.12363.
60. Erkan D., Unlu O., Sciascia S. et al. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus. 2018;27(3):399–406. DOI: 10.1177/0961203317724219.
61. Mekinian A., Lazzaroni M.G., Kuzenko A. et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study, Autoimmun Rev. 2015;14(6):498–502. DOI: 10.1016/j. autrev.2015.01.012.
62. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20–8. DOI: 10.1136/ard.2008.101766.
63. Tektonidou M.G., Laskari K., Panagiotakos D.B., Moutsopoulos H.M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61(1):29–36. DOI: 10.1002/art.24232.
64. Jung H., Bobba R., Su J. et al. The protective effect of antimalarial drugs on thrombus vascular events in systemic lupus erythematosus. Arthritis Rheum. 2010;62(3):863–8. DOI: 10.1002/art.27289.
65. Broder A., Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol. 2013;40(1):30–3. DOI: 10.3899/jrheum.120157.
66. Nuri E., Taraborelli M., Andreoli L. et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res. 2017;65(1):17–24. DOI: 10.1007/s12026–016–8812-z.
67. Schreiber K., Breen K., Parmar K. et al. The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology (Oxford). 2018;57(1):120–4. DOI: 10.1093/rheumatology/kex378.
68. Bertolaccini M.L., Contento G., Lennen R. et al. Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. J Autoimmun. 2016;75:30–8. DOI: 10.1016/j.jaut.2016.04.008.
69. Wu X.X., Guller S., Rand J.H. Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. Am J Obstet Gynecol. 2011;205(6):576.e7–14. DOI: 10.1016/j.ajog.2011.06.064.
70. Rand J.H., Wu A.A., Quinn A.S. et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112(5):1687– 95. DOI: 10.1182/blood-2008–03–144204.
71. Marchetti T., Ruffatti A., Wuillemin C. et al. Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies. J Thromb Haemost. 2014;12(6):910–20. DOI: 10.1111/jth.12570.
72. Espinola R.G., Pierangeli S.S., Gharavi A.E. et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost. 2002;87(3):518–22.
73. Ioannou Y., Lambrianides A., Cambridge G. et al. B cell depletion therapy for patients with systemic lupus erythaematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis. 2008;67(3): 425–6. DOI: 10.1136/ard.2007.078402.
74. Erkan D., Vega J., Ramón G. et al. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65(2):464–71. DOI: 10.1002/art.37759.
75. Berman H., Rodríguez-Pintó I., Cervera R. et al. Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. Autoimm Rev. 2003;12(11):1085–90. DOI: 10.1016/j.autrev.2013.05.004.
76. Yazici A., Yazirli B., Erkan D.Belimumab in primary antiphospholipid syndrome. Lupus. 2016;26(10):1123–4. DOI: 10.1177/0961203316682102.
77. Emmi G., Bettiol A., Palterer B. et al. Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment. Autoimmun Rev. 2019;18(3):312–4. DOI: 10.1016/j.autrev.2018.11.002.
78. Stohl W., Hiepe F., Latinis K.M. et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328–37. DOI: 10.1002/art.34400.
79. Van den Hoogen L.L., Palla G., Bekker Cp.J. et al. Increased Bcell activating factor (BAFF)/B-lymphocyte stimulator (BLyS) in primary antiphospholipid syndrome is associated with higher adjusted global antiphospholipid syndrome scores. RMD Open. 2018;4(2): e000693. DOI: 10.1136/rmdopen-2018–000693.
80. Sciascia S., Rubini E., Radin M. et al. Anticardiolipin and antibeta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab. Ann Rheum Dis. 2018;77(11):1694–5. DOI: 10.1136/annrheumdis-2018–213496.
81. Lonze B.E., Singer A.L., Montgomery R.A. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010;362(18):1744–5. DOI: 10.1056/nejmc0910965.
82. Gustavsen A., Skattum L., Bergseth G. et al. Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: A case report. Medicine (Baltimore). 2017;96(11): e6338. DOI: 10.1097/md.0000000000006338.
83. Meroni P.L., Macor P., Durigutto P. et al. Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood. 2015;127(3);365–7. DOI: 10.1182/blood-2015–09–672139.
84. Cervera R. CAPS Registry. Lupus. 2012;21(7):755–7. DOI: 10.1177/0961203312436866.
85. Kim M.Y., Guerra M.M., Kaplowitz E. et al. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Ann Rheum Dis. 2018;77(4):549–55. DOI: 10.1136/annrheumdis-2017–212224.
86. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10(11):1222–6. DOI: 10.1038/nm1121.
87. Arachchillage D.R.J., Mackie I.J., Efthymiou M. et al. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism. J Thromb Haemost. 2016;14(11):2177–86. DOI: 10.1111/jth.13475.
88. Canaud G., Bienaimé F., Tabarin F. et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014;371(4):303–12. DOI: 10.1056/nejmoa1312890.
89. Mora-Ramirez M., Gonzalez-Pacheco H., Amezcua-Guerra L. Stents coated with mammalian target of rapamycin inhibitors (mTOR) appear to Be the best choice in patients with antiphospholipid syndrome and myocardial infarction. J Clin Rheumatol. 2016;22(5):281. DOI: 10.1097/RHU.0000000000000409.
90. Alijotas-Reig J., Esteve-Valverde E., Llurba E. et al. Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: maternal-fetal outcomes in a series of 18 cases. Semin Arthritis Rheum. 2019;49:314e8. DOI: 10.1016/j.semarthrit.2019.02.006.
91. Rubbia-Brandt L. Sinusoidal obstruction syndrome. Clin Liver Dis. 2010;14(4):651–68. DOI: 10.1016/j.cld.2010.07.009.
92. Falanga A., Vignoli A., Marchetti M., Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia. 2003;17(8):1636–42. DOI: 10.1038/sj. leu.2403004.
93. Pescador R., Porta R., Ferro L. An integrated view of the activities of defibrotide. Semin Thromb Hemost. 1996;22(Suppl 1):71–5. 95. Unlu O., Erkan D. Catastrophic antiphospholipid syndrome: candidate therapies for a potentially lethal disease. Annu Rev Med. 2017;68:287–96. DOI: 10.1146/annurev-med-042915–102529.
94. Burcoglu-O’Ral A., Erkan D., Asherson R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol. 2002;29(9):2006–11. 97. Ali R., Meng H., Yalavarthi S. et al. Adenosine receptor agonism protects against antiphospholipid antibody-mediated netosis and venous thrombosis: meeting abstract. 2017 ACR/ARHP Annual Meeting, San Diego, 2017. Abstract: 2761.
95. DEFITELIO (defibrotide sodium) injection, for intravenous use Initial U.S. Approval: 2016. FAD Administration, 2016. 11 pр. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208114lbl.pdf. [Accessed: 10.04.2020].
96. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin. Guidance for Industry. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2017. 11 рp. Available at: https://www.fda.gov/files/ drugs/published/ANDAs-for-Certain-Highly-Purified-SyntheticPeptide-Drug-Products-That-Refer-to-Listed-Drugs-of-rDNAOrigin-Guidance-for-Industry.pdf. [Accessed: 10.04.2020].
97. Usmani S.S., Bedi G., Samuel J.S. et al. THPdb: Database of FDAapproved peptide and protein therapeutics. PLoS One. 2017;12: e0181748. DOI: 10.1371/journal.pone.0181748.
98. Garber A.J., Abrahamson M.J., Barzilay J.I. et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm — 2019 Executive Summary. Endocr Pract. 2019;25:69–100. DOI: 10.4158/CS-2018–0535.
99. Andrade D., Cervera R., Cohen H. et al. Antiphospholipid Syndrome. In: 15th International Congress on antiphospholipid antibodies task force on antiphospholipid syndrome treatment trends report. Eds. D. Erkan, M.D. Lockshin. Springer, Cham, 2017. 317– 38. DOI: 10.1007/978–3–319–55442–6_18.
100. Mcdonnell T., Pericleous C., Ioannou Y. et al. 029 Pegylated recombinant domain I of beta-2-glycoprotein I, a potential therapeutic agent for anti-phospholipid syndrome, fully retains its ability to inhibit binding of IgG or IgA antibodies from patients with anti-phospholipid syndrome to beta-2-glycoprotein I in vitro. Rheumatology. 2016;55(Suppl 1):i48-i49. DOI: 10.1093/rheumatology/kew105.004.